` CLSD (Clearside Biomedical Inc) vs S&P 500 Comparison - Alpha Spread

CLSD
vs
S&P 500

Over the past 12 months, CLSD has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's 5% growth.

Stocks Performance
CLSD vs S&P 500

Loading
CLSD
S&P 500
Add Stock

Performance Gap
CLSD vs S&P 500

Loading
CLSD
S&P 500
Difference

Performance By Year
CLSD vs S&P 500

Loading
CLSD
S&P 500
Add Stock

Competitors Performance
Clearside Biomedical Inc vs Peers

S&P 500
CLSD
LLY
JNJ
NOVO B
ROG
Add Stock

Clearside Biomedical Inc
Glance View

Market Cap
62.9m USD
Industry
Pharmaceuticals

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

CLSD Intrinsic Value
0.6529 USD
Overvaluation 21%
Intrinsic Value
Price
Back to Top